Navigation Links
Primary Progression-Free Survival Endpoint Met in Phase III Study of Nintedanib Plus Docetaxel in Second-Line Advanced NSCLC
Date:6/3/2013

RIDGEFIELD, Conn., June 3, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced  results from the Phase III LUME-Lung 1 study showing that the addition of the investigational oncology compound nintedanib* to docetaxel improved progression-free survival (PFS) – the primary endpoint – as a second-line treatment in patients with advanced non-small cell lung cancer (NSCLC) compared to docetaxel alone.1 Secondary endpoints included overall survival (OS).1 These results will be presented today at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).

"We are pleased to present the progression-free survival and overall survival data observed with the nintedanib/docetaxel combination in the LUME-Lung 1 clinical trial, in patients with advanced non-small cell lung cancer in the second-line treatment setting," said Berthold Greifenberg , MD, vice president, Clinical Development and Medical Affairs, Oncology, Boehringer Ingelheim Pharmaceuticals, Inc. "These results were selected by ASCO for presentation at a late-breaking oral session at this year's annual meeting."

The trial enrolled 1,314 patients with advanced NSCLC whose disease progressed after first-line chemotherapy.1 Patients were randomly assigned to receive nintedanib plus docetaxel (n=655), a standard second-line chemotherapy, or docetaxel plus placebo (n=659).1

The primary endpoint was PFS as assessed by central independent review; results showed patients treated with nintedanib plus docetaxel lived for a median of 3.4 months before their tumor started to grow again, versus 2.7 months with docetaxel alone (HR 0.79; p=0.0019).1 

The secondary endpoint of OS was evaluated in the full study population, as well as in the sub-group of patients with adenocarcinoma histology &
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
2. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
3. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly
4. Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients
5. MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models
6. Addisons Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
7. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
8. Genetic clues to the causes of primary biliary cirrhosis
9. CSL Behring Partners with Pro Supercross Racer Carl Schlacht to Encourage Those with Primary Immunodeficiency to be a "ChamPIon"
10. BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004)
11. Mayo Clinic and ReachMD Launch “Updates from Mayo Clinic” Featuring Expert Interviews and Panel Discussions on Mental Health in Pediatric Primary Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Pa. , July 28, 2015 ... and Drug Administration has accepted for review the company,s ... factor VIII single-chain (rVIII-SingleChain) for the treatment of hemophilia ... primary endpoints. Hemophilia A ... defective factor VIII; nearly all affected patients are male. ...
(Date:7/27/2015)... , July 27, 2015  Amgen (NASDAQ: ... second quarter financial results on Thursday, July 30, 2015, ... announcement will be followed by a conference call with ... the call from Amgen will be Robert A. ... members of Amgen,s senior management team. Live ...
(Date:7/27/2015)... ... July 27, 2015 , ... Brady ... new video: 3 Ways to GHS Labels . This video provides useful ... Harmonized System (GHS) by effectively labeling chemical containers. , “With the fourth and ...
(Date:7/27/2015)... NEW YORK , July 27, 2015 /PRNewswire-USNewswire/ ... today announced the winners of its annual ... basic research by scientists who have been supported ... early career scientists to pursue innovative ideas in ... generate "proof" of concept for the early detection, ...
Breaking Biology Technology:U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2Brady Releases “3 Roads to GHS Labels” Video 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6
... DECATUR, Ill., Oct. 29 Archer Daniels ... industrial chemicals group with a focus,on dramatically increasing ... ADM,s processing expertise, fermentation and,separation technologies and global ... chemicals by working to commercialize,additional chemicals from renewable ...
... Innovator in,Ultrasound for more than 50 years, announced today ... advanced cardiac and,vascular imaging, the ProSound Alpha 10 and ... Heart Association, at the Orange County,Convention Center in Orlando, ... and the Alpha 10 incorporate all of the standard,cardiovascular ...
... at American Academy of Pediatrics National Conference & ... ... NORRITON, Pa., Oct. 29 Tengion,Inc., a leader in regenerative medicine, ... the American Academy of,Pediatrics (AAP) National Conference and Exhibition demonstrate the ...
Cached Biology Technology:ADM Forms Industrial Chemicals Group 2ALOKA to Introduce New 'ProSound' Diagnostic Ultrasound Systems at the Scientific Session 2007 of American Heart Association, 4th to 7th of November 2007 in Orlando, Florida 2ALOKA to Introduce New 'ProSound' Diagnostic Ultrasound Systems at the Scientific Session 2007 of American Heart Association, 4th to 7th of November 2007 in Orlando, Florida 3Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function 2Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function 3
(Date:6/24/2015)... NEW YORK , June 24, 2015 ... favorable rate. The major drivers for the market include ... increasing number of new drug launches. Over the years, ... has increased. Between 2001 and 2010, the FDA approved ... addition, according to WIPO, Europe ...
(Date:6/24/2015)... June 22, 2015 ... addition of the "Huawei Ascend Mate 7 ... to their offering. Huawei,s technological choice ... opposite direction than Apple,s and Samsung,s one. The ... developed by Fingerprint Cards, a main actor in ...
(Date:6/23/2015)... Research and Markets( ... "Body-Worn Temperature Sensors Market - Global Industry ... - 2020" report to their offering. ... global body-worn temperature sensors market. The global body-worn ... basis of types, care setting, patient demographic, applications ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... treatment of Parkinson's disease blocks the stimulating effects of cocaine ... cocaine abuse, new research shows. , In an article published ... Neuroscience, Jonathan Katz and his colleagues at the National Institute ... that mice treated with a substance similar to the drug ...
... Johns Hopkins researchers have identified the proteins that allow specific ... what can come into the cell. The findings, described in ... the process, perhaps one day using it to protect cells ... the television dial changes what comes into the living room, ...
... study identifies a critical inhibitory step that is ... the balance between neutrophil production and destruction. The ... suggests that the process for disposal of dying ... clear understanding of the processes that control neutrophil ...
Cached Biology News:Potential Drug Target For Treating Cocaine Abuse Found 2Some Brain Cells 'Change Channels' To Fine-tune The Message 2Some Brain Cells 'Change Channels' To Fine-tune The Message 3White Blood Cell 'Waste Disposal' System Plays Critical Regulatory Role 2
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Rabbit polyclonal to FANCG ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSRQTTSVGSSC, corresponding to amino acids 1 - 12 of Human FANCG. Entrez GeneID: 2189 Swis...
Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6...
...
Biology Products: